|
|
| Industrie Pharmaceutique > Etude de marché sectorielle |
| The World Diabetes Market, 2005-2011 |
|
|
|
|
€ 2 219,00 |
Editeur
: |
Visiongain |
Langue
: |
Anglais |
Date de publication : |
Mars 2006 |
Taille du document : |
176 |
Autres informations : |
Description , Table des matières |
| |
|
|
|
|
| |
Documents Publics |
1,200,000
documents |
Téléchargement illimités |
|
|
|
Etudes Privées |
50,000 rapports et études |
Paiement à la piéce |
|
|
|
|
| |
|
1.Télécharger nos rapports publics
Accés complet à plus de 1,2 Million de documents publics : études de marché, statistiques sectorielles, fiches pays, monographie d'entreprises, veille concurentielle, rapports annuels...
|
| Nos documents publics sur le même théme (1) |
|
|
|
| 55 pages | Août 2001 | Anglais
|
|
|
| Main
focus: |
diabetic,vitamin,nutraceutical,vitamins
|
| Research
focus: |
market size and estimates,industry structure, |
| Geographic
focus: |
usa,croatia |
| |
|
|
|
|
| Autres recherches sur le même thème |
|
|
|
| |
| |
|
| |
|
2.
Rechercher d'autres rapports et études à commander
Rechercher et commander ici parmi 50.000 études de marché publiées par les principaux instituts d'études internationaux
|
| Rapports privés en relation |
|
The Drug Delivery Outlook 2001
176 pages | Juillet 2001 |
In an environment where there is constant pressure to launch new products onto the market, the cost of investment in drug delivery compares very favourably with new drug discovery.
Subseque |
955,00 €
|
| |
| |
The Pharmaceutical Distribution Outlook 1998-2008
165 pages | Octobre 1998 |
Industry growth and consolidation means that pharmaceutical manufacturers are no longer geographically limited in their operations and now market their products globally, creating a vast commercia |
795,00 €
|
| |
| |
The Pharmacogenomics Outlook
174 pages | Août 2000 |
Pharmaceutical companies are coming under increasing pressure to increase the quality of their products, and optimize and accelerate drug discovery and development.
By identifying differenc |
955,00 €
|
| |
| |
The Diagnostics Outlook to 2005
130 pages | Février 1999 |
Diagnostic market : The current in vitro diagnostic (IVD) market is discussed, identifying how the market can be segmented according to country, end user, clinical speciality and disease area.
795,00 €
|
|
| |
| |
The CNS Outlook 1998-2010
201 pages | Août 1999 |
In 1998, the CNS market expanded by 12.8%, growing in value from $29.4bn in 1997 to almost $33bn in 1998.
Expansion is being driven by the introduction of new technologies and products which are ra |
795,00 €
|
| |
| |
Maximising the Drug Lifecycle
102 pages | Août 2001 |
Up to $100bn of the 2000 pharmaceutical market, including blockbuster drugs with combined sales of $34bn will be exposed to generic competition by 2005.Maximising The Drug Lifecycle provides a detaile |
955,00 €
|
| |
| |
The CNS Outlook 2000
203 pages | Octobre 2000 |
The Central Nervous System (CNS) market has shown sustained growth in 1999 with the expansion continuing to be driven by several factors.A greater understanding of the neuropharmacological mechanisms |
955,00 €
|
| |
| |
European Pharmaceutical Industry
35 pages | Juillet 2002 |
The Pharmaceutical industry remains one of Europe’s best performing sectors (employment, R&D and trade surplus).
The world pharmaceutical market was worth an estimated € 392,640 million (at ex-fact |
600,00 €
|
| |
| |
Chinese Markets for Pharmaceuticals
225 pages | Janvier 2002 |
China's demand for pharmaceuticals has grown at a fast pace in the past decade.
In the next five years, both production and demand will continue to grow.
This new study examines China's economic |
2 835,00 €
|
| |
| |
Strategic Intelligence: The Top 12 Pharmaceutical Companies
158 pages | Novembre 2001 |
The pressure on the pharmaceutical company R&D has never been greater.
It is estimated that $100 billion worth of products will face patent expiry by 2005.
Of this, $37 billion represe |
1 021,89 €
|
| |
| |
|
| |
| Autres secteurs en relation |
|
|
|
| |
|
| |
| |
| Présentation de l'étude de marché - Description & Table des matières |
|
| The World Diabetes Market, 2005-2011 |
|
|
Diabetes effects approximately 170 million people worldwide and is increasing, with the WHO predicting 300 million diabetics by 2025. The US alone has 20.8 million people suffering with diabetes. This equates to approximately 6% of the population. It was the 6th most common cause of death as recorded on US death certificates.
The Global Diabetes drugs treatment market was valued of $15 billion in 2005. Oral anti-diabetics were the leading category of drugs - $8.19 billion - and showed a growth rate of 6.3% from the total global sales in 2004. The total sales for insulin products increased by 16.5% to total global sales of $6.83 billion in 2004.
Key Market for the Future…
Visiongain predicts that the retail market for diabetes medications will continue to show significant growth for what is an already large market. Actos from Takeda is the leading oral anti-diabetic product and appears set to retain this status. However, it is co-marketed with Eli Lilly which has new products to make available. Lantus from Sanofi-Aventis is the leading insulin product. But there are three new products available, including the world’s first inhaled insulin product – Exubera from Pfizer.
Why you should buy this report:
Diabetes treatment is a leading therapeutic area and is about to become even more important.
The world’s first inhaled insulin product has just been approved to the world’s largest pharmaceutical company. This report will help you to assess just what impact that this is likely to have.
The market is dominated by a Japanese product – is this a sign of things to come from a previously struggling side of the industry?
Visiongain has taken the latest available financial statistics and forecast revenue figures for all the leading products.
The report contains analysis of the pipeline and potential blockbuster products of the next five years.
|
|
The World Diabetes Market, 2005-2011
|
|
|
PPLSEN
|
|
|
|
|
